Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
October 16, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Third Quarter Financial Results
October 10, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 29, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
August 22, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 31, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
REPL
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
July 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 25, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
May 08, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 02, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
May 01, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 20, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
April 18, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
March 27, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
March 03, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 16, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
February 07, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
January 24, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
January 17, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.